Apixaban vs Aspirin for Afib

By  |  February 12, 2011 | 

Apixaban is a new oral Factor Xa inhibitor (similar to rivaroxaban). In this large trial of patients with afib and at least 1 risk factor for stroke, who were deemed “unsuitable” for warfarin, they were randomized to apixaban (5mg po BID) or aspirin (81mg-324mg/day); after 1.1 years of follow up, the apixaban group had significantly fewer stroke/emboli than the aspirin group (1.6% vs 3.7%), with no significant differences in mortality or bleeding. In patients unable or unwilling to take warfarin, apixaban may be a reasonable alternative (if / when it is FDA approved for afib, and pending evaluation of how much it will cost) (abstract)

About the Author:

Danielle Scheurer
Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.


Related Posts

By  | July 5, 2016 |  0
What comes to mind when you think of getting CME? I bet most of you would say sitting in an auditorium, whether that be during your local grand rounds or at our professional society meeting, like Hospital Medicine 16 in sunny San Diego this past March. Hanging out in the Twitterverse? Probably not so much… […]
By  | December 3, 2013 |  1
As a nurse practitioner in hospital medicine I have multiple opportunities to interact with all sorts of physician hospitalist colleagues, hospital medicine group leaders, quality officers etc.  Often their interactions with me take on a certain wary curiosity, like I am some exotic monkey or another creature that is unfamiliar to them.  If I am […]
By  | September 24, 2013 |  2
By reading the headlines recently, practitioners would not know if they saved or tanked the healthcare system.  One day disaster looms, the next we have moderated growth and business can continue as usual (and by business, I mean doing the correct things correctly). A new study, along with some recent data, helps shed some light […]

Leave A Comment